TG THERAPEUTICS, INC.: 10-Q filed 2014-07-24

Name: TG THERAPEUTICS, INC.: 10-Q filed 2014-07-24
Creator: TG THERAPEUTICS, INC.

What TG THERAPEUTICS, INC. reported in its quarterly report filed 2014-07-24 (fiscal Q2 2014): 24 published measures, 63 facts as tagged in accession 0001144204-14-044721.

This filing

Form: 10-Q (quarterly report)
Filed: 2014-07-24
Fiscal period: fiscal Q2 2014
Accession: 0001144204-14-044721 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All TG THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2014-06-30	56,302,299	USD
At 2013-12-31	48,112,390	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2014-06-30	4,206,484	USD
At 2013-12-31	8,057,898	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2014-06-30	37,077,977	USD
At 2013-12-31	40,485,466	USD
At 2013-06-30	13,416,952	USD
At 2012-12-31	16,455,995	USD

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2014-01-01 to 2014-06-30	3,165	USD	181
2013-01-01 to 2013-06-30	1,672	USD	181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2014-06-30	-58,937,682	USD
At 2013-12-31	-39,404,003	USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Value	Unit	Days
2012-01-01 to 2012-12-30	330,000	USD	365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2014-06-30	7,326	USD
At 2013-12-31	5,718	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	7,738,846	USD	91
2014-01-01 to 2014-06-30	11,970,284	USD	181
2013-01-01 to 2013-06-30	3,259,245	USD	181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	-11,955,497	USD	91
2014-01-01 to 2014-06-30	-19,560,622	USD	181
2013-04-01 to 2013-06-30	-6,628,765	USD	91
2013-01-01 to 2013-06-30	-10,342,806	USD	181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2014-06-30	49,286,908	USD
At 2013-12-31	42,303,263	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	234,787	USD	91
2014-01-01 to 2014-06-30	461,127	USD	181
2013-04-01 to 2013-06-30	240,014	USD	91
2013-01-01 to 2013-06-30	471,486	USD	181

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2014-06-30	2,606,484	USD
At 2013-12-31	6,317,178	USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

Period	Value	Unit	Days
At 2014-06-30	799,391	USD
At 2013-12-31	799,391	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	11,993,592	USD	91
2014-01-01 to 2014-06-30	19,636,812	USD	181
2013-04-01 to 2013-06-30	6,666,860	USD	91
2013-01-01 to 2013-06-30	10,418,996	USD	181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	6,848,132	USD	91
2014-01-01 to 2014-06-30	11,258,000	USD	181
2013-04-01 to 2013-06-30	5,027,623	USD	91
2013-01-01 to 2013-06-30	6,597,528	USD	181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2014-06-30	38,120,655	shares
At 2013-12-31	34,294,926	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2014-06-30	111,229,666	USD
At 2013-12-31	79,658,490	USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

Period	Value	Unit	Days
At 2014-06-30	52,095,815	USD
At 2013-12-31	40,054,492	USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2014-06-30	98,365	USD
At 2013-12-31	85,121	USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	-11,986,430	USD	91
2014-01-01 to 2014-06-30	-19,533,679	USD	181
2013-04-01 to 2013-06-30	-6,584,552	USD	91
2013-01-01 to 2013-06-30	-10,258,163	USD	181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	5,145,460	USD	91
2014-01-01 to 2014-06-30	8,378,812	USD	181
2013-04-01 to 2013-06-30	1,639,237	USD	91
2013-01-01 to 2013-06-30	3,821,468	USD	181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2014-01-01 to 2014-06-30	1,558	USD	181
2013-01-01 to 2013-06-30	309	USD	181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	-30,933	USD	91
2014-01-01 to 2014-06-30	26,943	USD	181
2013-04-01 to 2013-06-30	44,213	USD	91
2013-01-01 to 2013-06-30	84,643	USD	181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2014-03-01 to 2014-03-11	18,100,000	USD	11

Inspect the source

Entity: TG THERAPEUTICS, INC. / CIK 0001001316
Captured: 2026-09-20 05:11 UTC
SEC response SHA-256: 153d276440c1903144d2ca193676af4b7014428a3e4b5524efe33528427880b3

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001001316.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))